Northwest Biotherapeutics, Inc. (NWBO) Announces Increase in Clinical Trial Sites for Its Immunotherapy Product DCVax®
Northwest Biotherapeutics, a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer, today announced that it is on target to fulfill its prior projection that it will have fifteen clinical trial sites open and active in Q3 of this year for its DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company now has twelve sites where there is an ongoing clinical trial of DCVax® immune therapy, including UCLA, New York University, Baylor Research Institute and Henry Ford Hospital. The Company’s…